
XON
Other · Other · $3.24B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2019
EPS trend, 90 days to now · -17.4% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 1, 2019 | Time not confirmed | -0.34 | -2.59 | -661.3% |
| Nov 9, 2018 | Time not confirmed | -0.27 | -0.44 | -63.9% |
| Aug 14, 2018 | Time not confirmed | -0.29 | -0.51 | -74.4% |
| May 11, 2018 | Time not confirmed | -0.19 | -0.33 | -73.1% |
| Mar 2, 2018 | Time not confirmed | -0.32 | -0.23 | +29.4% |
Precigen, Inc. engages in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control…